Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Neuronal Identity Established by Specific Transcription Factors

By LabMedica International staff writers
Posted on 21 May 2018
A team of neurodegenerative disease researchers has developed a protocol for the consistent transformation of stem cells of fibroblast origin into specific classes of neurons for brain research and drug development.

Transient expression of certain transcription factors has been found to endow non-neural cells with neuronal properties. More...
The relationship between reprogramming factors and the transcriptional networks that produce neuronal identity and diversity remains largely unknown.

To study this process, investigators at The Scripps Research Institute (La Jolla, CA; USA) screened 598 pairs of transcription factors in a mouse model system.

They reported in the May 9, 2018, online edition of the journal Nature that 76 pairs of transcription factors (12.7%) induced mouse fibroblasts to differentiate into cells with neuronal features. By comparing the transcriptomes of these induced neuronal cells (iN cells) with those of natural neurons, the investigators defined a "core" cell-autonomous neuronal signature. The iN cells also exhibited diversity; each transcription factor pair produced iN cells with unique transcriptional patterns that could predict their pharmacological responses. By linking distinct transcription factor input "codes" to defined transcriptional outputs, these findings delineated cell-autonomous features of neuronal identity and diversity and expanded the reprogramming toolbox to facilitate engineering of induced neurons with desired patterns of gene expression and related functional properties.

"The brain is incredibly complex, with thousands of different types of cells that are each involved in different diseases," said senior author Dr. Kristin Baldwin, a professor at the Scripps Research Institute. "The problem with understanding and treating the many disorders of the brain is that we cannot reproducibly produce the right types of brain cells. Now we have found more than 75 new ways to rapidly and reproducibly turn skin cells into neurons that we think will be much better representatives of different neurologic diseases than were previously available. Having a personalized and nearly unlimited supply of different types of neuronal cells in a dish lets you uncover what is going wrong in a disease. At the same time, the study supplies a new toolkit to test thousands of drugs on the affected cells to try to reverse the problems, rather than having to test them in mice or other animals, with results that are often difficult to interpret for human conditions."

Related Links:
The Scripps Research Institute


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.